Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Pfizer Inc. < Previous 1 2 3 4 5 6 7 8 9 10 Next > Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets September 25, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union September 20, 2024 From Pfizer Inc. Via Business Wire Tickers BNTX PFE Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts September 17, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia September 14, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer September 14, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 September 11, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference August 28, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare August 27, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine August 22, 2024 From Pfizer Inc. Via Business Wire Tickers BNTX PFE Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age August 16, 2024 From Pfizer Inc. Via Business Wire Tickers BNTX PFE Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults August 12, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance July 30, 2024 From Pfizer Inc. Via Business Wire Tickers PFE European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B July 25, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate July 24, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron July 11, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development July 09, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Cyrus Taraporevala Elected to Pfizer’s Board of Directors July 01, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union June 27, 2024 From Pfizer Inc. Via Business Wire Tickers BNTX PFE Pfizer Declares Third-Quarter 2024 Dividend June 26, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts June 18, 2024 From Pfizer Inc. Via Business Wire Tickers PFE ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma June 14, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy June 12, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference June 03, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) June 01, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression May 31, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Announces New Chief Strategy and Innovation Officer May 06, 2024 From Pfizer Inc. Via Business Wire Tickers PFE Pfizer Reports First-Quarter 2024 Results May 01, 2024 From Pfizer Inc. Via Business Wire Tickers PFE FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer April 29, 2024 From Pfizer Inc. Via Business Wire Tickers GMAB PFE Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting April 29, 2024 From Pfizer Inc. Via Business Wire Tickers PFE U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B April 26, 2024 From Pfizer Inc. Via Business Wire Tickers PFE < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.